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Campylobacter jejuni is a major cause of bacterial diarrheal disease worldwide. The organism is characterized by a diversity of
polysaccharide structures, including a polysaccharide capsule. Most C. jejuni capsules are known to be decorated nonstoichio-
metrically with methyl phosphoramidate (MeOPN). The capsule of C. jejuni 81-176 has been shown to be required for serum
resistance, but here we show that an encapsulated mutant lacking the MeOPN modification, an mpnC mutant, was equally as
sensitive to serum killing as the nonencapsulated mutant. A nonencapsulated mutant, a kpsM mutant, exhibited significantly
reduced colonization compared to that of wild-type 81-176 in a mouse intestinal colonization model, and the mpnC mutant
showed an intermediate level of colonization. Both mutants were associated with higher levels of interleukin 17 (IL-17) expres-
sion from lamina propria CD4 cells than from cells from animals infected with 81-176. In addition, reduced levels of Toll-like
receptor 4 (TLR4) and TLR2 activation were observed following in vitro stimulation of human reporter cell lines with the kpsM
and mpnC mutants compared to those with wild-type 81-176. The data suggest that the capsule polysaccharide of C. jejuni and
the MeOPN modification modulate the host immune response.
Campylobacter jejuni is one of the major causes of bacterial diarrheaworldwide. The organism is unusual among enteric pathogens in
that it expresses a polysaccharide capsule (CPS) that contributes to
serum resistance, invasion of intestinal epithelial cells in vitro, and
virulence in ferret and Galleria mellonella larvae models of disease
(1–3). CPS is the major serodeterminant of the Penner serotyping
scheme of C. jejuni (4), in which there are 47 serotypes, a reflection of
the diversity of polysaccharide capsular structures in C. jejuni. In ad-
dition to variation in sugar composition, the CPS can be modified
with ethanolamine, glycerol, and O-methyl phosphoramidate
(MeOPN). The MeOPN modification, which is found on about 75%
of C. jejuni CPSs, has been shown to modulate cytokine release from
mouse dendritic cells and to be a key determinant in virulence in the
moth larva model of disease (2, 3). Both CPS expression itself (1) and
expression of the modifications are phase variable due to slip strand
mismatch repair (5–7). Thus, reversible phase variations in multiple
genes result in mixed populations of wild-type cells, some of which
express CPS and others that do not (1). Similarly, the levels of the
MeOPN modifications found on the CPS are present in nonstoichio-
metric amounts because of phase variation in genes encoding the
enzymes involved in transfer of these groups to specific sugars (8).
We have shown that a polysaccharide conjugate vaccine com-
posed of the capsule of strain 81-176 conjugated to carrier protein
CRM197 showed significant protection against diarrheal disease in a
nonhuman primate model of diarrhea, also suggesting a role for CPS
in virulence (9). Here, we further demonstrate that the CPS and the
MeOPN modification both play significant roles in modulation of
several aspects of the immune response, including serum resistance,
activation of NF-B, and cytokine induction in vivo.
MATERIALS AND METHODS
Bacterial strains and media. C. jejuni strain 81-176, its motile, isogenic
kpsM mutant, and the complement of that mutant have been described
previously (1). Bacteria were routinely cultivated microaerobically on
Mueller-Hinton (MH) agar supplemented with antibiotics as appropri-
ate. For serum resistance assays, strains were grown in biphasic MH cul-
tures for 18 to 20 h at 37°C. For mouse infection studies, strains were
inoculated in MH broth to an optical density at 600 nm (OD600) of 0.01
to 0.05 and incubated with shaking under microaerobic conditions at
37°C for 18 h.
Mutation and complementation of a gene for biosynthesis of
MeOPN in C. jejuni 81-176. A region of the CPS locus of the 81-176
chromosome carrying genes for MeOPN synthesis (8) was cloned as a
PCR fragment into BamHI-digested pBluescript. The primers used were
pg08.90 (CGGGATCCGGAATGCCTGCTGTTATAGGAGTTGGA) in
CJJ81176_1417 (labeled mpnA in Fig. 1) and pg08.91 (CGGGATCCCAT
CGAAGCATCATCTTCAACTTGAGC) in CJJ81176_1413 (kpsC). Both
primers introduced a BamHI site at the 5= ends, indicated by the under-
lining. The resulting plasmid was subjected to transposon mutagenesis
using an in vitro Tn5-based transposition system (Epicentre, Madison,
WI) with a chloramphenicol resistance (Cmr; cat) cassette, and the
insertion points were identified by sequencing individual insertions
with primers within the cassette, as previously described (10–12). A
clone with a nonpolar insertion into gene CJJ81176_1415 (mpnC in
Fig. 1) was identified; the insertion was 472 bp into the 762-bp gene.
This plasmid was used to electroporate C. jejuni 81-176 to Cmr, and
the resulting mutant was confirmed to have undergone a double cross-
over by PCR with primers that bracketed the insertion point of the
transposon. The mutant was complemented by cloning a wild-type
allele of mpnC into pRY107/28, which is pRY107 (13) containing the
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28 promoter of flaA cloned between the XbaI and BamHI sites. The
wild-type mpnC gene was PCR amplified using high-fidelity polymer-
ase (Clontech) and primers pg08.155 (5=-CGGGATCCGGTATAATGT
GGCATATTGAAAGAG-3=) and pg08.150 (5=-CCGCTCGAGCTCTTA
ACTCATCTCCATCGAGATAAATAAG-3=), which introduced BamHI
and XhoI sites, respectively. This fragment was cloned into BamHI-XhoI-
digested pRY107/28. The plasmid complement was introduced into 81-
176 mpnC by conjugal transfer from E. coli DH5 containing RK212.2, as
previously described, with selection on kanamycin (14).
31P NMR spectrometry. Preparations containing the CPSs were dis-
solved in D2O, and
31P nuclear magnetic resonance (NMR) was per-
formed on a 400-MHz Bruker NMR instrument. Orthophosphoric acid
was used as the external reference ( 0.00).
Serum survival assays. Cultures (18 h old) of C. jejuni grown in MH
biphasic media were washed and adjusted to an OD600 of 0.1 in minimal
essential medium (MEM). Aliquots (100 l) were added to wells of a
24-well plate containing 900 l of prewarmed MEM supplemented with
10% normal human serum (Sigma; NHS) and incubated under mi-
croaerobic conditions at 37°C. The percentage of survivors was deter-
mined by serial dilution onto MH agar plates. Assays were run in duplicate
3 or 4 times.
Mouse infection experiments. BALB/c mice (7 to 8 weeks old; Jack-
son Laboratories, Bar Harbor, ME) were housed in groups of 10 with
access to food and water ad libitum. For infection with C. jejuni, 1 liter of
broth culture was harvested by centrifugation and resuspended in phos-
phate-buffered saline (PBS). The inocula were normalized by OD600 to
1011 CFU/ml, and animals were inoculated intragastrically with 100 l
of the cell suspension. The inoculum doses were validated on MH agar
plates prior to and immediately after infection of the animals. All animal
experiments were conducted in compliance with the Animal Welfare Act
and in accordance with the principles set forth in the Guide for the Care
and Use of Laboratory Animals (15).
Assessment of colonization. Fecal collections were performed by al-
lowing individual mice to defecate in clean, empty shoebox cages prior to
returning to group housing. Feces were collected using forceps into 5-ml
Falcon snap-cap tubes and then diluted 1:10 by weight into PBS. Various
stool dilutions were plated onto campylobacter selective media (CVA
plates; Remel) and incubated under microaerobic conditions at 42°C for 2
days.
Lymphocyte isolation. At various time points following oral chal-
lenge, mice were sacrificed and small intestines were removed to recover
lamina propria lymphocytes (LPLs) as described previously (16), with
some modifications. In brief, Peyer’s patches (PP) were removed from the
intestines and intestines were cleared of contents using forceps, opened
longitudinally, and then cut into 5-mm sections. Intraepithelial lym-
phocytes (IELs) were removed from these intestinal sections by placing
the tissue in a solution of 1 mM dithiothreitol (DTT) and 1 mM EDTA at
37°C for two 20-min incubations. After each incubation, the supernatant
was removed and replaced with fresh DTT-EDTA. To isolate LPLs, the
remaining intestinal pieces were digested with collagenase D (Roche; 1
mg/ml) and DNase I (Sigma; 40 g/ml) for two 1-h incubations at 37°C.
The supernatant was removed following each incubation and replaced
with fresh medium. Following the digestion of small intestinal tissue sec-
tions, cells were pelleted by centrifugation and LPLs were isolated using a
discontinuous (80 to 40%) Percoll gradient.
FIG 1 (A) Diagram of the capsule locus of strain 81-176. The locus is organized, like other class 2 capsule loci, into conserved regions 1 and 3, encoding proteins
involved in capsule assembly and transport, and the variable region 2, encoding proteins involved in polysaccharide synthesis. The MeOPN biosynthesis genes
(mpnA to -D) are found within region 2 but are highly conserved among strains if present and correspond to CJ1415 to CJ1418 in NCTC 11168 (8). Genes
corresponding to CJJ81176_1418 and CJJ81176_1419 are also highly conserved among strains expressing MeOPN, but mutational analyses have failed to
demonstrate a role for these genes in MeOPN synthesis (16). CJJ81176_1420 is annotated as a putative MeOPN transferase. There are 15 additional genes within
region 2 of 81-176. (B) 31P NMR of CPSs from wild-type 81-176 (blue), the mpnC mutant (green), and the mpnC mutant complemented in trans (red).
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Intracellular cytokine staining. LPLs were cultured in vitro for 4 to 6
h in the presence of medium alone or phorbol-12-myristate-13-acetate
(PMA) (Sigma; 20 ng/ml) and ionomycin (Sigma; 0.5 g/ml). Medium
was Dulbecco modified Eagle medium (DMEM) supplemented with 10%
fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES, 1 mM
sodium pyruvate, nonessential amino acids, 50 M 2-mercaptoethanol,
penicillin (100 IU/ml), and streptomycin (100 g/ml). Protein transport
was inhibited with the addition of brefeldin A (10 g/ml). Following
culture, LPLs were stained with CD4 allophycocyanin (APC). Cells were
fixed in 4% formaldehyde prior to permeabilization with 0.1% saponin
(in PBS and 1% FBS). Intracellular staining was performed using anti-
mouse gamma interferon (IFN-) fluorescein isothiocyanate (FITC)
(eBioscience) or anti-mouse interleukin 17 (IL-17) phycoerythrin (PE)
(eBioscience). Cells were then washed and resuspended in 1% formalde-
hyde prior to analysis on a Becton, Dickinson FACScan equipped with red
and blue lasers (i.e., 5-color capability). Data were analyzed using FlowJo
software (TreeStar).
TLR signaling assay using whole bacteria. The following cell lines
were purchased from InvivoGen: HEK-Blue-hTLR4, HEK-Blue-hTLR2,
and THP1-XBlueTM-MD2-CD14. Human epithelial kidney (HEK) 293
cells are stably transfected with either human Toll-like receptor 4
(hTLR4), MD2, and CD14 (HEK-Blue-hTLR4) or hTLR2 and CD14
(HEK-Blue-hTLR2). THP1-XBlueTM-MD2-CD14 cells are derived from
the human monocytic THP-1 cell line and are stably transfected with
MD2 and CD14. These HEK-Blue and THP1-XBlue clones also stably
express secreted embryonic alkaline phosphatase (SEAP) under the con-
trol of a promoter inducible by NF-B and activator protein 1 (AP-1).
Thus, stimulation of Toll-like receptors will result in an amount of extra-
cellular SEAP in the supernatant that is proportional to the level of NF-B
induction. The HEK cell lines were maintained in standard DMEM with
10% heat-inactivated FBS (Gibco) supplemented with 4.5 g/liter of glu-
cose, 2 mM L-glutamine, 50 U/ml of penicillin, 50 g/ml of streptomycin,
100 g/ml of Normocin (InvivoGen), and 1 HEK-Blue selection (Invi-
voGen) in a 5% saturated CO2 atmosphere at 37°C. The THP-1 cell line
was maintained in standard RPMI 1640 medium with 10% heat-inacti-
vated FBS (Gibco) supplemented with 4.5 g/liter of glucose, 2 mM L-glu-
tamine, 1.5 g/liter of sodium bicarbonate, 10 mM HEPES, 1 mM sodium
pyruvate, 50 U/ml of penicillin, 50 g/ml of streptomycin, 100 g/ml of
Normocin (InvivoGen), 200 g/ml of Zeocin (InvivoGen), and 250
g/ml of G418 (InvivoGen) in a 5% saturated CO2 atmosphere at 37°C.
The induction of TLR signaling in HEK-Blue-hTLR4, HEK-Blue-
hTLR2, and THP1-XBlueTM-MD2-CD14 clones was assessed by mea-
suring SEAP activity using the QUANTI-Blue colorimetric assay (Invivo-
Gen). The assays were performed according to the manufacturer’s
protocols. Briefly, cells were seeded in a 96-well plate in triplicate (2.5 
104 cells/well for HEK-Blue-hTLR4, 5  104 cells/well for HEK-Blue-
hTLR2, and 1  105 cells/well for THP1-XBlueTM-MD2-CD14). Whole
bacterial cells were grown on Mueller-Hinton agar for 16 h, collected from
the plate, washed, and resuspended in sterile PBS. Serial dilutions (10-
fold) were prepared based on OD600 to yield the number of bacteria inoc-
ulated into each well. CFU were confirmed by plating serial dilutions on
MH agar. Erythromyin (50 g/ml) was included to prevent bacterial
growth during incubation, and other antibiotics used in the media for cell
propagation were omitted in the assay. After 18 h of incubation, superna-
tants (20 l) were transferred to a 96-well plate and incubated at 37°C
with QUANTI-Blue (180 l). SEAP activity was measured by reading the
OD655 with a Synergy Mx multimode microplate reader (BioTek).
Statistical analyses. Differences in mouse colonization level, as as-
sessed by the number of organisms shed (log10 CFU/gram of feces), were
compared using a repeated-measures analysis of variance with the C. je-
juni strain as the between-animal factor (i.e., wild type, kpsM mutant, and
mpnC mutant) and collection time points as the repeated factor. The
covariance structure was modeled using a first-order antedependence
model. A Tukey adjustment was utilized to control the type I error rate.
Comparisons of the proportions of mice infected by strains over time were
made using a Cox proportional-hazards model. These analyses were con-
ducted with SAS, version 9.2, for Windows (SAS Institute, Inc., Cary,
NC), using a two-tailed alpha of 0.05.
Statistical analyses of complement killing, intracellular cytokine ex-
pression, and TLR assays were conducted using Student’s t test. Differ-
ences were considered significant at a P value of 	0.05.
RESULTS
Construction of a mutant in the MeOPN biosynthetic pathway
of 81-176. McNally et al. (8) identified the genes in C. jejuni strain
NCTC 11168 (CJ1415 to CJ1418) that were responsible for
MeOPN synthesis, as well as two distinct MeOPN transferases that
were responsible for attachment of MeOPN to two different sites
in the CPS of this strain. CJ1415 to CJ1418 are highly conserved
among C. jejuni strains, while the transferases are more variable
based on differences in attachment of the MeOPN to sugars. The
genes corresponding to CJ1415 to CJ1418 in 81-176 are
CJJ81176_1414 to CJJ81176_1417. Since the function of genes has
been established in NCTC 11168, we have named the genes for
MeOPN synthesis mpnA to -D, shown in Fig. 1A, for clarity in
discussing these conserved genes in different strains. A mutant
with a mutation in mpnC in 81-176 was shown to lack MeOPN by
31P NMR, as predicted based on the NCTC 11168 data (8), and
MeOPN was restored when the mutant was complemented
(Fig. 1). The mpnC mutant produced CPS as determined by both
NMR and immunoblotting with rabbit polyclonal antibody to
whole cells of 81-176 (data not shown).
MeOPN contributes to serum resistance. There have been
several reports demonstrating that nonencapsulated mutants of
C. jejuni are more sensitive to normal human serum than wild-
type strains (1, 17). Data comparable to those published for 81-
176 and its isogenic kpsM mutant (1) are shown in Fig. 2. Surpris-
ingly, the mpnC mutant, expressing the polysaccharide CPS
lacking MeOPN, displayed the same pattern of serum killing as the
kpsM mutant, which lacked all CPS (Fig. 2). The mpnC mutant
was significantly more sensitive than the wild type to complement
at both 60 min (P 	 0.001) and 120 min (P 	 0.005). When the
mpnC mutant was complemented in trans, serum resistance re-
turned to levels comparable to those of the wild type (Fig. 2).
Capsule is required for prolonged mouse colonization. The
abilities of the kpsM and mpnC mutants to colonize mice were
compared to that of the wild type in a series of experiments. Ani-
mals were intragastrically infected with C. jejuni, and colonization
was monitored postinfection by fecal shedding. Following infec-
FIG 2 Sensitivities of 81-176 and mutants to complement killing by NHS. The
percentages of survivors after 60 and 120 min of incubation with 10% NHS are
shown. Black, 81-176; red, kpsM mutant; green, mpnC mutant; blue, mpnC
mutant complemented in trans.
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tion, wild-type C. jejuni 81-176 colonized mice on average at levels
exceeding 106 CFU/g of feces (Fig. 3A). This high level of coloni-
zation was maintained for more than 15 days before counts began
to drop below the initial colonization levels. Mice infected with
the kpsM mutant generally had early colonization levels similar to
that of the wild type (Fig. 3A). In addition, the kpsM-infected mice
had a shorter duration of colonization than did those infected
with the wild type (P 
 0.06). The majority of kpsM-infected mice
cleared the infection by day 18, in contrast to the wild-type-in-
fected mice, which remained colonized at some level through day
28 postinfection (the last day tested) (Fig. 3A). Thus, despite the
similar levels of colonization seen early postinfection, by day 14,
there was a statistically significant difference in colonization levels
of mice infected with kpsM compared to those infected with the
wild type (P 	 0.01).
In parallel experiments, the colonization capacity of the mpnC
mutant was compared to that of the wild type. Upon infection
with the mpnC mutant, mice shed numbers of C. jejuni organisms
in their stool similar to those shed by mice infected with the wild
type (Fig. 3B). In fact, there were no significant differences in stool
counts between the mpnC mutant and the wild type during the
first 10 days postinfection, and only later in infection did the
mpnC mutant demonstrate a significant reduction in the level of
colonization compared to that of the wild type (Fig. 3B; P 
 0.02
for day 20). Thus, although not directly compared, the coloniza-
tion ability of the mpnC mutant appeared intermediate in nature
compared to those of the wild type and the kpsM mutant (Fig. 3).
IL-17 expression from intestinal T cells is modulated by the
CPS. To determine if CPS had a role on immune responses in vivo,
mice were orally infected with wild-type 81-176 and the mpnC or
kpsM strain. At selected times postinfection, T cells were isolated
from small intestine Peyer’s patches, the epithelium, and the lam-
ina propria. Following an ex vivo restimulation, the levels of ex-
pression of IL-17 and IFN- were determined using intracellular
cytokine staining and flow cytometry. Figure 4A and B show rep-
resentative histograms for CD4 LPLs and dot plots demonstrating
gating strategies for intracellular cytokine staining. Following in-
fection with either the kpsM or wild-type strain, CD4 cells from
the lamina propria of kpsM mutant-infected mice exhibited sig-
nificantly higher percentages (P 	 0.05) of CD4 cells that ex-
pressed IL-17 at day 7 and day 21 (Fig. 4C). No difference was
observed in IFN- expression of CD4 LPLs isolated from kpsM
mutant- or wild-type-infected mice at either time point. Differ-
ences in cytokine expression were not observed from PP cells or
IELs (data not shown).
Next, the MeOPN modification on CPS was examined for its
role in modulating immune responses in vivo. CD4 LPLs from
mpnC-infected mice did not express significantly higher percent-
ages of IL-17 cells on day 7 than did LPLs isolated from mice
orally challenged with wild-type 81-176 (Fig. 4D). However, on
day 21 postinfection, mice colonized by mpnC exhibited signifi-
cantly higher percentages (P 	 0.01) of CD4 LPLs expressing
IL-17 than animals infected with the wild type. In addition, no
significant differences were seen in other lymphocyte subsets or in
IFN- expression patterns (data not shown).
Effects of CPS on TLR signaling. To determine the impact of
CPS production and modification on TLR activation, we per-
formed reporter cell signaling assays with whole bacteria. The
kpsM mutant exhibited significantly higher activation than the
wild type from 104 to 107 CFU for hTLR4 activation and from 105
to 108 CFU for hTLR2 activation (Fig. 5). Although similar results
were seen with the mpnC mutant, the lack of complete comple-
mentation confounds these results (data not shown).
We subsequently compared the overall TLR activation of
kpsM and mpnC mutants using a human monocytic reporter
line that expresses several TLRs, including TLR1, TLR2, TLR4,
TLR6, TLR8, NOD1, and NOD2. Significant increases (P 	
0.005) in signaling were observed for both mutant strains com-
pared to the wild type and their complements (Fig. 6). For the
kpsM mutant, these differences were observed from 104 to 107
CFU, and for the mpnC mutant, the differences were observed
between 105 and 107 CFU.
DISCUSSION
C. jejuni remains a poorly understood pathogen, in part because of
the absence of small-animal models that mimic human disease.
Following orogastric infection with C. jejuni, adult, immunocom-
petent mice can become colonized for variable lengths of time, but
without the disease symptoms seen in immunodeficient mice (18–
23). Despite the lack of disease, the mouse model can provide
information on traits required for colonization, the first step in
pathogenesis (23). Here, we show that wild-type 81-176 colonizes
BALB/c mice better than either an isogenic mutant lacking capsule
(kpsM mutant) or a mutant expressing CPS without MeOPN
(mpnC mutant). Interestingly, a reduction in colonization ability
of an MeOPN-negative mutant of 81-176 (in the gene corre-
FIG 3 Colonization of BALB/c mice by C. jejuni strain 81-176 and various CPS mutants. The log CFU/g of feces shed by the wild type and either a kpsM mutant
(A) or an mpnC mutant (B) are shown over the course of infection. Groups of 10 mice were intragastrically infected with 1010 CFU. Each data point represents
an individual mouse infected with the wild type (squares) or a mutant (circles), and the group mean is displayed as a connected line (solid for the wild type and
dashed for mutants). The limit of detection was 102 CFU/g of feces. These data are representative of 3 or 4 independent experiments.
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sponding to mpnA) compared to wild-type 81-176 was also re-
ported with MyD88-defective mice (24). In our studies, BALB/c
mice that were colonized with wild-type 81-176 remained colo-
nized for the duration of the experiments (21 days). The kpsM
mutant showed similar colonization levels for about 9 days before
colonization levels dropped. The mpnC mutant colonized at levels
that were generally lower than those of the wild type, although
statistical significance was reached only at day 20. Thus, expres-
sion of CPS by C. jejuni facilitated colonization in the mouse
model. CPS has also been shown to play a role in C. jejuni coloni-
zation of chickens (25, 26).
Following restimulation, IL-17 production by CD4 LPLs was
reduced in mice colonized by C. jejuni 81-176 compared to both
mutant strains. Mice colonized by either the kpsM or mpnC mu-
tant possessed higher levels of IL-17 CD4 cells in the small
intestine than did mice colonized by the wild type at day 21, and
this increased IL-17 production was associated with a reduction in
colonization levels. However, despite the fact that both the kpsM
mutant and the mpnC mutant were associated with higher fre-
quencies of IL-17-producing CD4 cells in the small intestine
than was wild-type 81-176, the kpsM mutant appeared to show a
greater reduction in colonization capacity than the mpnC mutant,
suggesting that the presence of the CPS, even without the MeOPN
modification, affords some protection against the immune re-
sponse in the intestine. Although in vivo cytokine responses were
not measured directly in this study, the data suggest that CPS
expression, and more specifically, the MeOPN modification on
the wild-type capsule, may affect the generation of IL-17 responses
in the gut mucosa. Future studies are needed to determine the
specificity of the IL-17 response against C. jejuni in the intestine.
FIG 4 IL-17 expression is reduced in small intestinal CD4 LPLs from mice infected with wild-type C. jejuni 81-176. BALB/c mice (4 or 5/group) were orally
infected with 1010 CFU of C. jejuni. At days 7 and 21 postinfection, small intestines were removed and processed to isolate LPLs. LPLs were restimulated in vitro
with PMA (20 ng/ml) and ionomycin (500 ng/ml) for 4 to 6 h. Protein transport was inhibited by addition of brefeldin A (10 g/ml). Intracellular cytokine
staining for IL-17 and IFN- was performed on cells and analyzed by flow cytometry. (A) Representative histograms demonstrating the percentages of CD4 and
CD8 cells isolated from mouse small intestines. (B) Representative dot plots demonstrating intracellular staining for IL-17 and IFN- in unstimulated and
stimulated CD4 LPLs. (C) Percent expression of IL-17 in CD4 LPLs from mice infected with kpsM mutant or wild-type C. jejuni. (D) IL-17 expression in CD4
LPLs from mice infected with mpnC mutant or wild-type C. jejuni. Data represent the means  standard errors of the means. *, P 	 0.05; **, P 	 0.01 (Student’s
t test). Data are representative of 2 or 3 independent experiments.
FIG 5 Activation of TLR4 in HEK 293 cells transfected with human TLR4-MD2-CD14 (A) and TLR2 in HEK 293 cells stably transfected with human
TLR2-CD14 (B). TLR activation was monitored colorimetrically using a SEAP reporter gene placed under the control of an NF-B inducible promoter.
Tenfold serial dilutions of whole bacterial cells of the indicated strains of C. jejuni were added to each well in triplicate. Values represent the means and
standard deviations of one experiment assayed in triplicate. The graphs are representative of three independent experiments. Asterisks indicate a P value
of 	0.005 compared to wild-type 81-176 or the complement. Black lines, wild-type 81-176; red lines, the isogenic kpsM mutant; blue lines, the kpsM
mutant complemented in trans.
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T helper 17 (Th17) responses have come into focus due to their
roles in maintaining intestinal homeostasis (27, 28) and protective
immune responses against enteric pathogens (28–31). The gut
Th17 response is composed of both innate and adaptive immune
system components. Innate Th17 (iTh17) responses are induced
by segmented filamentous bacteria (SFB) that colonize the gut
(32, 33) and maintain a symbiotic balance between the microbiota
and host (28). Specific animal vendors supply mice that are either
colonized with SFB or not (Jackson Laboratories, SFB; Taconic,
SFB) (33). These models can be exploited to evaluate innate or
adaptive Th17 responses. Whereas iTh17 responses can be in-
duced relatively quickly by cytokine signals (29, 30), adaptive
Th17 responses occur later (days to weeks) (34) and are antigen-
specific responses. In our present study, the Th17 responses likely
represented an adaptive immune response, since Jackson Labora-
tory mice were used. Key to Th17 responses are the cytokines
IL-17 and IL-22 and the upstream cytokines that lead to their
expression, such as IL-1, IL-6, and IL-23 (34–36). IL-17 is primar-
ily thought to be effective against extracellular pathogens by in-
ducing inflammation and recruiting neutrophils to sites of infec-
tion (reviewed in reference 35). IL-22 exerts its protective effects
by inducing epithelial cells to produce antibacterial molecules
(37). Recently, Th17 responses have been demonstrated to have
protective roles against Salmonella and Citrobacter infections in
mice (29, 30). To date, only limited data exist regarding Th17
responses and Campylobacter infection. Edwards et al. (38)
showed that cytokines involved in Th17 responses were induced
in colon biopsy tissues following coculture with C. jejuni and that
the addition of exogenous IL-17 reduced C. jejuni invasion into an
intestinal epithelial cell line. However, additional work must be
performed to determine the precise role of Th17 immune re-
sponses to C. jejuni.
Consistent with these data, we have also shown that the pres-
ence of the CPS on wild-type 81-176 resulted in reduced activation
of both TLR2 and TLR4 using HEK cells expressing each receptor.
Our data are consistent with those of Rose et al. (3), who showed
that mutants of NCTC 11168 lacking CPS or MeOPN induced
higher levels of IL-6, tumor necrosis factor alpha (TNF-), and
IL-10 from mouse dendritic cells than did the wild-type strain.
Using dendritic cells from TLR4/ mice, they also showed that
some of these differences in cytokines were due to TLR4 signaling.
Similar downregulation of the immune response has been ob-
served for other bacterial capsules (39–44). In some cases, this
inhibition may be due to shielding of the bacterial surface by the
capsule and prevention of TLR stimulation. However, the CPS of
Neisseria meningitidis actively inhibits TLR2 activation by binding
CD14 (45). The MeOPN modification on two distinct CPS struc-
tures of C. jejuni has now been shown to modulate cytokine re-
sponses and TLR signaling (3), suggesting an active role for this
unusual structure. Similarly, the C. jejuni CPS may inhibit binding
of complement activators and components to the surface of the
bacterial cell, but the fact that the mpnC mutant was as sensitive as
the kpsM mutant to complement killing also suggests an active
role for the MeOPN group. In contrast to C. jejuni, modification
of Haemophilus influenzae lipopolysaccharide with phosphory-
choline, which is also under phase-variable expression, enhances
sensitivity to complement killing (46). The mechanism by which
MeOPN interacts with components of the complement cascade is
under investigation.
Collectively, these data indicate that CPS of 81-176 and the
MeOPN modification modulate the immune response to this
pathogen and are consistent with previous observations suggest-
ing a stealth strategy by which C. jejuni may avoid the immune
response. It has been known for some time that C. jejuni flagellin is
unable to induce TLR5 because of structural changes to the mo-
nomeric subunit protein that are reflected in changes in filament
formation (47, 48). C. jejuni also expresses altered linkages of hy-
droxyacyl chains on lipid A that reduce TLR4 activation (49), and
there is evidence that the N-linked glycan on proteins and certain
lipooligosaccharide glycoforms can downregulate IL-6 induction
(50). Previous work has shown that the CPS of NCTC 11168, and
specifically the MeOPN modification on this CPS, reduced cyto-
kine production from mouse dendritic cells in culture (3). Here,
we have demonstrated that a second C. jejuni CPS and the MeOPN
modification modulate the immune response at multiple levels,
including resistance to complement killing and cytokine induc-
tion via NF-B signaling. The ability to avoid the immune re-
sponse of the host provides an advantage in establishing coloniza-
tion by C. jejuni, be it as a commensal in animals or as a pathogen
in humans. Moreover, asymptomatic infection by C. jejuni is com-
mon among children in the developing world, and acute infec-
tions are frequently followed by periods of asymptomatic shed-
FIG 6 Activation of Toll-like receptors using a human monocytic (THP-1) reporter cell line by kpsM (A) and mpnC (B) mutants compared to wild-type 81-176
and complements of each mutant. Bacteria were added to cells as described in the legend to Fig. 5. Values represent the means and standard deviations of one
experiment assayed in triplicate. The graphs are representative of three independent experiments. Asterisks indicate a P value of 	0.005 compared to wild-type
81-176 or the complement. Black lines, 81-176; red line, the isogenic kpsM mutant; green line, the isogenic mpnC mutant; blue lines, the complement of each
mutant.
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ding (51–53), which may be due, at least in part, to the ability of
this pathogen to avoid the host immune response. Similarly, re-
crudescence of infection following appropriate antibiotic treat-
ment in an immunocompetent adult has been reported (54).
One of the hallmark characteristics of C. jejuni is its ability to
undergo phase variation of surface antigens by slip strand mis-
match repair (1, 7, 55–58). In terms of the CPS, this phase varia-
tion occurs at two levels. One is the high frequency on/off revers-
ible expression that was originally described to occur in strain
81-176, such that a culture grown in vitro is a mixed population of
encapsulated and unencapsulated variants (1). The other level of
phase variation affects CPS structure and is best understood in
terms of the MeOPN modification. Thus, all MeOPN transferases
that have been described to date are subject to phase variation at
homopolymeric tracts of bases, resulting in nonstoichiometric
amounts of this modification. The reason for this variability in
both CPS expression and structure is not understood, but the data
presented here suggest that the CPS, with and without MeOPN,
modulates the host immune response at multiple levels. Since C.
jejuni produces an inflammatory diarrhea, phase variation during
replication in vivo may also modulate the severity of illness and, at
least in part, explain variability in severity of symptoms seen with
this pathogen.
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